EPC 2021 Updates in Pulmonary Disease

January 7, 2021 to January 10, 2021

Didactic lectures allow the speakers to provide evidence based medical recommendations, updates and expert opinion.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology and the Eastern Pulmonary Conference.  The American College of Allergy, Asthma and Immunology is accredited by the ACCME to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 14.25 contact hours.

This activity is not supported by commercial support.

Target Audience

Practicing allergists, pulmonologists and allied healthcare professionals in the field of allergy, asthma and immunology.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Discuss the role of alarmins in the pathogenesis of asthma and how monoclonal antibodies against alarmins may be of therapeutic benefit.
  • Outline how molecular phenotyping of asthma can drive therapeutic decisions
  • Discuss the use of oxygen therapy in the critically ill patient: the costs of too much and too little oxygen therapy
  • Describe new GINA recommendations regarding the use of short acting beta agonists
  • Apply current evidence-based practices to managing uncontrolled asthma
  • Explain the clinical presentations, treatments and outcomes of nosocomial pneumonia
  • Outline current evidence regarding antibiotic resistance and practical approaches to manage resulting clinical challenges
  • Discuss the epidemiology, burden of illness and pathophysiology of pulmonary hypertension and apply new treatment options for this disease
  • Explain the recent advances in understanding the natural history and pathogenesis of interstitial lung disease and the use of anti-fibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
  • Outline the recent advances in our understanding of biomarkers in the management of COPD
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

Course summary
Available credit: 
  • 14.25 AMA PRA Category 1 Credit™
  • 14.25 Attendance
  • 14.25 CBRN
Course opens: 
Course expires: 
Event starts: 
01/07/2021 - 3:55pm CST
Event ends: 
01/10/2021 - 9:30am CST

All identified conflicts of interest have been mitigated.

The individuals listed below disclose the following financial relationships:

Sidney Braman, MD – Planner, Moderator, Speaker
Consultant – AstraZeneca
Speaker – Genentech

William Corrao, MD – Moderator, Speaker
Speaker – GlaxoSmithKline, Boehringer Ingelheim
Advisory Board – GlaxoSmithKline 

Marilyn Glassberg, MD – Speaker 
Advisory Board –Bellerophon, Boehringer Ingelheim, Genentech

Terrill Huggins, MD – Speaker
Author – Up to Date

Barry Make, MD – Speaker
Consultant – AstraZeneca, GlaxoSmithKline, Circassia, Verona, Walters Kluwer, UpToDate, Boehringer Ingelheim, Takeda, Phillips
Speaker – Sunovion 

Maria Padilla, MD – Speaker
Consultant – Boehringer Ingelheim, Best Doctors
Speaker – France Foundation, Genentech, Takeda, Paradigm Medical
Author – Up to Date
Panelist – Vindico Medical Education

Rey Panettieri Jr., MD – Planner, Speaker
Speaker – AstraZeneca, Sanofi, Genentech
Consultant – RIFM
Advisory Board - AstraZeneca, MedImmune, Equillium, Theravance, Avillion, 
Independent Contractor – AstraZeneca, MedImmune, RIFM, Equillium, Genentech, Theravance, OncoArendi, 

Charles Powell, MD – Speaker
Independent Contractor – Alexion
Consultant – Daiichi Sankyo, AstraZeneca, Johnson & Johnson

M. Patricia Rivera, MD – Speaker
Consultant – Johnson & Johnson
Advisory Board – bioAffinity Technologies, Biodesix

Russell Settipane, MD – Planner, Moderator, Speaker, Reviewer
Speaker – ALK, Genentech, Pharming, Regeneron, Shire, Sunovion, Teva, Boehringer Ingelheim
Consultant – Boehringer Ingelheim, RB Health 
Advisory Board – ALK, AstraZeneca, Genentech, Regeneron, Sanofi, Teva, Pharming, GlaxoSmithKline
Independent Contractor – AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Novartis, Teva, Syneos Health, BioCryst, Avillon

Andy Shorr, MD – Speaker
Speaker – Merck, Tetraphase
Independent Contractor – Merck
Consultant – Merck, Pfizer, Tetraphase, Shionogi

Momen Wahidi, MD – Speaker
Consultant – Olympus, Pulmonx, Cook

Sally Wenzel, MD – Speaker
Consultant – AstraZeneca, Sanofi

Robert Wise, MD – Speaker
Consultant – AstraZeneca, Boehringer Ingelheim, Chiesi, Galderma, GlaxoSmithKline, Merck, Novartis, Kiniksa, Kinevant, Anaptsysbio, PureTech, Contrafect, Kamada, FSD Pharma
DSMB – AbbVie
Independent Contractor – Sanofi
Advisory Board – Chimers, Arrowhead

The following have no relevant financial relationships to disclose:
Sakahi Dua, MD – Speaker
Katelyn Loiselle, RN – Planner
Lawrence Mohr, MD – Speaker
Curt Sessler, MD – Speaker
Ganesh Raghu, MD – Speaker
Ginny Loiselle – Coordinator

Available Credit

  • 14.25 AMA PRA Category 1 Credit™
  • 14.25 Attendance
  • 14.25 CBRN
Please login or create an account to take this course.